Infectious mononucleosis in patients with inflammatory bowel disease under treatment with azathioprine;Mononucleosis infecciosa en pacientes con enfermedad inflamatoria intestinal en tratamiento con azatioprina

Gastroenterologia y Hepatologia

Volumn 31, Issue 5, 2008, Pages 289-292

  Bargalló, Ana ^a   Carrión, Silvia ^a   Domènech Morral, Eugeni ^a   Arévalo, Juan Antonio ^b   Mañosa, Míriam ^a   Cabré, Eduard ^a   Cabriada, José Luis ^b   Gassull, Miquel Àngel ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL DE GALDAKAO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; INFLIXIMAB; STEROID; VALGANCICLOVIR;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; ENTERITIS; HUMAN; INFECTIOUS MONONUCLEOSIS; LABORATORY TEST; MALE;

EID: 43449089489     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13119881     Document Type: Article

References (40)

1. E. Cabré Indicaciones de la azatioprina (o 6-mercaptopurina) en la enfermedad inflamatoria intestinal Gastroenterol Hepatol 25 2006 319 326
2. C. Cara A.S. Peña M. Sans L. Rodrigo M. Guerrero-Estero J. Hinojosa Reviewing the mechanism of action of thiopurine drugs: towards a new paradigm in clinical practice Med Sci Monit 10 2004 247 254
3. J.P. Gisbert F. Gomollón J. Mate J.M. Pajares Preguntas y respuestas sobre el papel de la azatioprina y la 6-mercaptopurina en el tratamiento de la enfermedad inflamatoria intestinal Gastroenterol Hepatol 25 2002 401 415
4. W.J. Sandborn A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate Am J Gastroenterol 91 1996 423 434
5. M. Lémann J.Y. Mary J.F. Colombel B. Duclos J.C. Soule E. Lerebours A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission with azathioprine Gastroenterology 128 2005 1812 1818
6. M. Villien J.F. Dahlerup L.K. Munck P. Norregaard K. Gronbaek J. Fallingbrog Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn’s disease: increasing relapse rate the following year Aliment Pharmacol Ther 19 2004 1147 1152
7. I. Bernal E. Domènech E. García-Planella E. Cabré M.A. Gassull Infecciones oportunistas en pacientes con enfermedad inflamatoria intestinal bajo tratamiento inmunosupresor Gastroenterol Hepatol 26 2003 19 29
8. M.A. Epstein A.J. Morgan Clinical consequences of Epstein-Barr virus infection and possible control by an anti-viral vaccine Clin Exp Immunol 53 1983 257 271
9. H. Kimura Pathogenesis of chronic active Epstein-Barr virus infection: is this an infectious disease, lymphoproliferative disorder, or immunodeficiency? Rev Med Virol 16 2006 251 261
10. Sandborn WJ, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azatioprina o 6-mercaptopurina para la inducción de la remisión en la enfermedad de Crohn (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 1. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com (traducida de The Cochrane Library. Issue 1. Chichester: John Wiley & Sons, Ltd.; 2007).
11. Pearson DC, May GR, Fick G, Sutherland LR. Azatioprina para el mantenimiento de la remisión en la enfermedad de Crohn (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 1. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com (traducida de The Cochrane Library. Issue 1. Chichester: John Wiley & Sons, Ltd.; 2007).
12. S. Ardizzone G. Maconi A. Russo V. Imbesi E. Colombo G. Bianchi Porro Ramdomised, controlled trial, of azathioprine and 5-aminosalicylic acid for the treatment of steroid-dependent ulcerative colitis Gut 55 2006 47 53
13. E. Domènech E. García-Planella I. Bernal Azathioprine without oral cyclosporine in the long-term maintenance of remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis Aliment Ther Pharmacol 16 2002 2061 2065
14. D.H. Present S.J. Meltzer M.P. Krumholz A. Wolke B.I. Korelitz 6-mercaptopurine in the management of the inflammatory bowel disease: short and long-term toxicity Ann Int Med 111 1989 641 649
15. A.G. Fraser T.R. Orchard D.P. Jewell The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review Gut 50 2002 485 489
16. Navarro Ortega D. Diagnóstico de la mononucleosis infecciosa causada por el virus de Epstein-Barr. Servicio de Microbiología. Hospital Clínico Universitario. Valencia. Control de Calidad de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Disponible en: http://www.seimc.org/control/revi_Sero/veb.htm
17. A. Garrido Serrano F. Pérez Martín F.J. Guerrero Igea J. Galbarro Muñoz S. Palomo Gil Mononucleosis infecciosa mortal durante el tratamiento con azatioprina en la enfermedad de Crohn Gastroenterol Hepatol 23 2000 7 8
18. E.F.M. Posthuma R.G.J. Westendorp A. Van der Sluys Veer J.C. Kluin-Nelemans Ph.M. Kluin C.B.H.W. Lamers Fatal infectious mononucleosis: a severe complication in the treatment of Crohn’s disease with azathioprine Gut 36 1995 311 313
19. B. Lobo B. Mínguez X. Molero F. Casellas Síndrome febril por infección por el virus del Epstein-Barr en la enfermedad de Crohn Med Clin (Barc) 120 2003 677 678
20. D.G. James C.D. Stone H.L. Wang W.F. Stenson Reactive hemophagocytic syndrome complicating the treatment of inflammatory bowel disease Inflamm Bowel Dis 12 2006 573 580
21. G. Bastida P. Nos M. Aguas B. Beltrán M. Rodríguez J. Ponce Optimización del tratamiento inmunomodulador con azatioprina o 6-mercaptopurina en pacientes con enfermedad inflamatoria intestinal Gastroenterol Hepatol 30 2007 511 517
22. D.W. Hanto G. Frizzera D.T. Purtilo K. Sakamoo J.L. Sullivan A.K. Saemudsen Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and the role of Epstein-Barr virus Cancer Res 41 1981 4253 4261
23. O.W. Kamel M. Van de Rijn L.M. Weiss G.J. Del Zoppo P.K. Hench B.A. Robbins Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis N Engl J Med 328 1993 1317 1321
24. I. Penn Post-transplant malignancy: the role of immunosupression Drug Saf 23 2000 101 113
25. J.L. Jones E.V. Loftus Lymphoma risk in inflammatory bowel disease: is it the disease or its trreatment? Inflamm Bowel Dis 13 2007 1299 1307
26. J. Askling L. Brandt A. Lapidus P. Karlén M. Björkholm R. Löfberg Risk of haematopoietic cancer in patients with inflammatory bowel disease Gut 54 2005 617 622
27. G.P. Aithal J.C. Mansfield Review article: the risk of lymphoma associated to inflammatory bowel disease and immunosuppressive treatment Aliment Pharmacol Ther 15 2001 1101 1108
28. A. Kandiel A.G. Fraser B.I. Korelitz C. Brensinger C. Lewis J.D. Lewis Increased risk of lymphoma among inflammatory disease patients treated with azathioprine and 6-mercaptopurine Gut 54 2005 1121 1125
29. G.A. Dayharsh E.V. Loftus Jr. W.J. Sandborn W.J. Tremaine A.R. Zinsmeister T.E. Witzig Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine Gastroenterology 122 2002 72 77
30. A. Losco H. Gianelli B. Cassani L. Baldini D. Conte G. Basilisco Epstein-Barr virus-associated lymphoma in Crohn’s disease Inflamm Bowel Dis 10 2004 425 429
31. L. Larvol J.C. Soule A. Le Tourneau Reversible lymphoma in the setting of azathioprine therapy for Crohn’s disease N Engl J Med 331 1994 883 884
32. S. Li M.J. Borowitz Primary Epstein-Barr virus-associated Hodgkin disease complicating of the ileum complicating Crohn disease Arch Pathol Lab Med 125 2001 424 427
33. D.M. Weinstock G.C. Ambrossi C. Brennan T.E. Kiehn A. Jakubowski Preemptive diagnosis and treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development Bone Marrow Transpl 37 2006 539 546
34. D. Reijasse C. Le Pendeven J. Cosnes A. Dehee J.P. Gendre J.C. Nicolas Epstein-Barr virus load in Crohn’s disease. Effect of immunosuppressive therapy Inflamm Bowel Dis 10 2004 85 90
35. A. Lavagna M. Bergallo M. Daperno R. Sostegni C. Costa R. Leto Infliximab and the risk of latent virases reactivation in active Crohn’s disease Inflamm Bowel Dis 13 2007 896 902
36. M. Okano T.G. Gross Advanced therapeutic and prophylactic strategies for Epstein-Barr virus infection in immunocompromised patients Expert Rev Anti Infect Ther 5 2007 403 413
37. D.P. Funch A.M. Walker G. Schneider N.J. Ziyadeh M.D. Pescovitz Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients Am J Transplant 5 2005 2894 2900
38. J.W.J. Van Esser H.G.M. Niesters B. Van der Holt E. Meijer A.D.E. Osterhaus J.W. Gratama Prevention of Epstein-Barr virus lymphoprolifertaive disease by molecular monitoring and preemptive rituximab in high-risk patients after allogenic stem cell transplantation Blood 99 2002 4364 4369
39. M. Slifkin S. Doran D.R. Snydman Viral prophylaxis in organ transplant recipients Drugs 64 2004 2763 2792
40. J. Duraiswamy M. Sherritt S. Thomson J. Tellam L. Cooper G. Connoly Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma Blood 101 2003 3150 3156